While the pandemic presses on, the healthcare industry has experienced a significant amount of change. New innovations, the understanding that the pandemic (and its effects) will undoubtedly linger on into the future, the growth of digital health, and hospitals’ struggle to keep up are all reshaping the industry as a whole — and creating new opportunities for dealmakers.
COVID-19 vaccine and test development has spurred on a number of new deals between investors and biotechnology and pharmaceutical companies. New private equity firms specializing in healthcare deals have been established. And within these deals, terms are now starting to include unique representations and warranties such as following CDC guidelines.
Note that a subscription is required to read the content in full.